Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

References

• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
   Google Scholar
• Devereux R, Beevers G, de Faire U, et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin 2007;23:259–270
   PubMed Web of Science ®Google Scholar
• Bang LE, Wiinberg N, Wachtell K, et al. Effect of atenolol and losartan on 24-hour ambulatory blood pressure in a subgroup of LIFE patients. J Hypertens 2004;22(Suppl 2):S112
   Web of Science ®Google Scholar
• Dahlöf B, Zanchetti A, Diez J, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J.Hypertens 2002;20:1855–64
   Google Scholar
• Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456–62
   PubMed Web of Science ®Google Scholar
• Gerdts E, Wachtell K, Omvik P, et al. Left atrial size and risk of major cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial) (abstract). Circulation 2003;108(Suppl IV):IV371
   Google Scholar
• Wachtell K, Hornestram B, Lehto M, et al. Cardiovascular mortality and morbidity in hypertensive patients with atrial fibrillation: the LIFE study. J Am Coll Cardiol 2005;45:705–11
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Hornestram B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for Endpoint reduction (LIFE) study J Am Coll Cardiol 2005;45:712–9
   Google Scholar
• Olsen MH, Wachtell K, Tuxen C, et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005;23:1083–90
   PubMed Web of Science ®Google Scholar
• Olsen MH, Wachtell K, Neland K, et al. Losartan but not atenolol reduces carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005;14:177–83
   PubMed Web of Science ®Google Scholar
• Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, et al. Effect of losartan on human platelet activation. J.Hypertens 1999;17:447–52
   Google Scholar
• Erdem Y, Usalan C, Haznedaroglu IC, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999;12:1071–6
   PubMed Web of Science ®Google Scholar
• Levy PJ, Yunis C, Owen J, et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000;86:1188–92
   PubMed Web of Science ®Google Scholar
• Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770–6
   PubMed Web of Science ®Google Scholar
• Høieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041–9
   Google Scholar
• Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004;22:1805–11
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20: 1879–86
   Google Scholar
• Olsen ME, Wachtell K, Beevers G, et al. Losartan has positive effects on lipid metabolism compared to atenolol in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study [abstract]. J Am Coll Cardiol 2005;45(Suppl A):423A
   Google Scholar
• Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684–9
   Google Scholar
• Safar ME, O’Rourke MF. Pulse pressure and antihypertensive agents. Hypertension 2005;46:e6
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213–25
   PubMed Web of Science ®Google Scholar
• Roman MJ, Kizer JR, Ali T, et al. Central blood pressure better predicts cardiovascular events than does peripheral blood pressure: the Strong Heart Study [abstract]. Circulation 2005;112(Suppl II):II778
   Google Scholar
• Kizer JR, Dahlöf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005;45:46–52
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–10
   Google Scholar
• Devereux RB, Dahlöf B, Kjeldsen SE, et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med 2003;139:169–77
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlöf B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint Reduction (LIFE) substudy. J Am Med Assoc 2002;288:1491–8
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux R, Kjeldsen S. Authors’ reply. Lancet 2004;364:413–4
   PubMed Web of Science ®Google Scholar
• Hart RG, Halperin JL, Pearce LA, et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003;138:831–8
   PubMed Web of Science ®Google Scholar
• Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, management. New York: Raven Press; 1995. p. 465–78
   Google Scholar
• Rothrock JF, Hart RG. Antithrombic treatment of cerebrovascular disease. In: Colman RW, Hirsh J, Marder VJ, editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott; 1994. p. 1438–51
   Google Scholar
• Chalmers J, Todd A, Chapman N, et al. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens 2003;21:651–63
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001;104:2039–44
   PubMed Web of Science ®Google Scholar
• Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994;89:724–30
   PubMed Web of Science ®Google Scholar
• Falk E, Shah PK, Fuster V. Pathogenesis of plaque disruption. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 491–507
   Google Scholar
• Schiffrin EL. Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 2002;15:115S–122S
   Google Scholar
• Cohn JN. Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making. Am J Hypertens 2001;14:258S–263S
   Google Scholar
• Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000;101:264–9
   PubMed Web of Science ®Google Scholar
• Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow’s triad revisited. Circulation 2000;101:218–20
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl J Med 1990;322:1561–6
   PubMed Web of Science ®Google Scholar
• Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345–52
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation 2003;108:684–90
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, et al. Regression of electro-cardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. J Am Med Assoc 2004;292:2343–9
   PubMed Web of Science ®Google Scholar
• Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. J Am Med Assoc 2004;292:2350–6
   PubMed Web of Science ®Google Scholar
• Pearson AC, Gudipati C, Nagelhout D, et al. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension. J Am Coll Cardiol 1991;17:422–30
   PubMed Web of Science ®Google Scholar
• Dunn FG, Chandraratna P, deCarvalho JG, et al. Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 1977;39:789–95
   PubMed Web of Science ®Google Scholar
• Tarazi RC, Miller A, Frohlich ED, Dustan HP. Electro-cardiographic changes reflecting left atrial abnormality in hypertension. Circulation 1966;34:818–22
   PubMed Web of Science ®Google Scholar
• Frohlich ED, Tarazi RC, Dustan HP. Clinical-physiological correlations in the development of hypertensive heart disease. Circulation 1971;44:446–55
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, D’Agostino RB, Belanger AJ, et al. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995;92:835–41
   PubMed Web of Science ®Google Scholar
• Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke 1999;30:2019–24
   PubMed Web of Science ®Google Scholar
• Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet 2006;367:262–72
   PubMed Web of Science ®Google Scholar
• Hart RG. Atrial fibrillation and stroke prevention. New Engl J Med 2003;349:1015–6
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006;47:46–50
   PubMed Web of Science ®Google Scholar
• Li Y, Li WM, Xue JY, et al. Effects of losartan on acute atrial electrical remodeling. Chin Med J [English] 2004;117:643–6
   Google Scholar
• Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197–204
   PubMed Web of Science ®Google Scholar
• Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612–7
   PubMed Web of Science ®Google Scholar
• Caballero R, Delpon E, Valenzuela C, et al. Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents. Circulation 2000;101:1199–205
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994;14:177–92
   PubMed Web of Science ®Google Scholar
• Olsen MH, Wachtell K, Neland K, et al. The effect of losartan versus atenolol on carotid artery hypertrophy in essential hypertension. A LIFE substudy [abstract]. Circulation 2002;106: II–574
   Web of Science ®Google Scholar
• Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653–9
   PubMed Web of Science ®Google Scholar
• Weir MR, Dzau VJ. The renin–angiotensin–aldosterone system: a specific target for hypertension management. Am J Hypertens 1999;12:205S–213S
   Google Scholar
• Olsen MH, Wachtell K, Aalkjaer C, et al. Endothelial dysfunction in resistance arteries is related to high blood pressure and circulating low density lipoproteins in previously treated hypertension. Am J Hypertens 2001;14:861–7
   PubMed Web of Science ®Google Scholar
• Spence JD. Cerebral consequences of hypertension. In: Laragh J, Brenner B, editors. Hypertension: pathophysiology, diagnosis, management. New York: Raven Press; 1995. p. 741–53
   Google Scholar
• Schiffrin EL. Reactivity of small blood vessels in hypertension: relation with structural changes. State of the art lecture. Hypertension 1992;19:II1-II9
   Google Scholar
• Schiffrin EL, Deng LY, Larochelle P. Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients. Clin Invest Med 1993;16:177–86
   Google Scholar
• Fogari R, Zoppi A, Malamani G, et al. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension. Curr Ther Res 2001;62:68–78
   Web of Science ®Google Scholar
• Mugellini A, Rinaldi A, Zoppi A, et al. Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus. J Cardiovasc Pharmacol 2005;45:310–3
   PubMed Web of Science ®Google Scholar
• Petrikova M, Jancinova V, Nosal R, et al. Antiplatelet activity of carvedilol in comparison to propranolol. Platelets 2002;13:479–85
   PubMed Web of Science ®Google Scholar
• Punda A, Polic S, Rumboldt Z, et al. Effects of atenolol and propranolol on platelet aggregation in moderate essential hyper-tension: randomized crossover trial. Croat Med J 2005;46:219–24
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. J Am Med Assoc 2000;283:2404–10
   Web of Science ®Google Scholar
• Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7–13
   PubMed Web of Science ®Google Scholar
• Breckenridge A. Hypertension and hyperuricaemia. Lancet 1966;1:15–8
   PubMed Web of Science ®Google Scholar
• Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149–54
   PubMed Web of Science ®Google Scholar
• Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens 1998;16: 761–9
   Google Scholar
• Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072–8
   PubMed Web of Science ®Google Scholar
• Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991–7
   PubMed Web of Science ®Google Scholar
• Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:12–7
   PubMed Web of Science ®Google Scholar
• Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998;29:635–9
   PubMed Web of Science ®Google Scholar
• Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951–6
   PubMed Web of Science ®Google Scholar
• Burnier M, Pechere-Bertschi A, Nussberger J, et al. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995;26:108–15
   PubMed Web of Science ®Google Scholar
• Hamada T, Hisatome I, Kinugasa Y, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793–7
   PubMed Web of Science ®Google Scholar
• Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268–71
   PubMed Web of Science ®Google Scholar
• Sasaki M, Fujimura A, Harada K, et al. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Pharmacol 1996;36:403–8
   PubMed Web of Science ®Google Scholar
• Puig JG, Mateos F, Buno A, et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033–9
   PubMed Web of Science ®Google Scholar
• Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002;20:347
   Google Scholar
• Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension [Losartan Trial Investigators]. Clin Ther 2000;22:1186–203
   PubMed Web of Science ®Google Scholar
• Sayin T, Doven O, Akyurek O, Dincer I. Neutral effect of valsartan on serum uric acid and renal function tests. J Hum Hypertens 2001;15:435–6
   PubMed Web of Science ®Google Scholar
• Zacks E, Wachtell K, Gerdts E, et al. Association of uric acid level with new-onset atrial fibrillation in treated hypertensive patients: the LIFE study [abstract]. Circulation 2005;112(Suppl 11):11–459
   Google Scholar
• Luft FC, Agrawal B. Microalbuminuria as a predictive factor for cardiovascular events. J Cardiovasc Pharmacol 1999;33\(Suppl 1):S11–5 [discussion S41–3.:S11–S15]
   Google Scholar
• Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin–angiotensin system. Drugs 2004;64:2537–65
   PubMed Web of Science ®Google Scholar
• Olsen MH, Fossum E, Hoieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005;23:891–8
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities study. New Engl J Med 2000;342:905–12
   PubMed Web of Science ®Google Scholar
• Fyhrquist F, Devereux R, Kjeldsen S, Dahlöf B. Response. Hypertension 2005;46:e6–e7
   Google Scholar
• Edelman JM, Lyle PA, Zhang Z. Letter to the editor. Ann Intern Med 2004;140:W–29
   Google Scholar
• Kato J, Eto T. Diuretics in the LIFE study. Lancet 2004;364:413–4
   PubMed Web of Science ®Google Scholar
• Anon. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288:2981–97
   Web of Science ®Google Scholar
• Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT – BPLA). Lancet 2005;366:907–13
   Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro-flumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT – BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906
   Google Scholar
• Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–86
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022–31
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359–65
   Google Scholar
• Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. J Am Med Assoc 2003;289:2073–82
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. J Am Med Assoc 2003;290:2805–16
   Google Scholar
• Williams B. VALUE and supremacy of blood pressure control for cardiovascular protection. J Hypertens 2004;22:1435–7
   PubMed Web of Science ®Google Scholar
• Staessen JA, Birkenhager WH. VALUE: to the heart of the matter. J Hypertens 2004;22:1431–4
   PubMed Web of Science ®Google Scholar
• Kario K, Pickering T. VALUE: analysis of results. Lancet 2004;364:934
   PubMed Web of Science ®Google Scholar
• Williams SG, Barker D, Schlosshan D, Tan LB. VALUE: analysis of results. Lancet 2004;364:932
   PubMed Web of Science ®Google Scholar
• Scheen AJ. VALUE: analysis of results. Lancet 2004;364:932–3
   PubMed Web of Science ®Google Scholar
• Sever P. VALUE: analysis of results. Lancet 2004;364:933–4
   PubMed Web of Science ®Google Scholar
• Fretheim A. VALUE: analysis of results. Lancet 2004;364:934–5
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Birkenhager WH. VALUE: analysis of results. Lancet 2004;364: 931
   PubMed Web of Science ®Google Scholar